[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Epiomic Epidemiology Series: Primary Myleofibrosis Forecast in 8 Major Markets 2016-2026

March 2016 | 40 pages | ID: EE0DB852C36EN
Black Swan Analysis limited

US$ 6,382.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Primary Myelofibrosis (PMF) in 8 Major Markets

Primary Myelofibrosis (PMF), also known as myelofibrosis, myeloid metaplasia or chronic idiopathic myelofibrosis, is part of the collection of diseases known as myeloproliferative neoplasms (MPNs). PMF is a chronic blood cancer that affects the haematopoietic system, causing progressive fibrosis of the bone marrow and impairs the ability of new blood cell production. Eventually, the bone marrow is unable to produce blood cells, and the spleen and liver take over the function causing abdominal swelling and discomfort.

This report provides the current prevalent population for PMF across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of PMF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PMF include:
  • Portal hypertension
  • Thrombosis
  • Anaemia
  • Gout
  • Extramedullary haematopoiesis
  • Leukocytosis
  • Splenomegaly
  • Acute myeloid leukaemia
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global PMF’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of PMF and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on PMF’s prevalent population.
  • Identify sub-populations within PMF which require treatment.
  • Gain an understanding of the specific markets that have the largest number of PMF patients.
Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Primary Myelofibrosis
Features of PMF Patients
  Staging and Scores of PMF
  Cell Counts in PMF Patients
  Associated Conditions of PMF
  JAK2 Mutation in PMF Patients
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

LIST OF TABLES

Prevalence of PMF, total (000s)
Prevalence of PMF, males (000s)
Prevalence of PMF, females (000s)
Dupriez score in PMF patients, total (000s)
Bone marrow staging in PMF patients, total (000s)
White blood cell count (x 109 /dL) in PMF patients, total (000s)
Platelet count (x 109 /dL) in PMF patients, total (000s)
Circulating blasts (%) in PMF patients, total (000s)
Hepatomegaly in PMF patients, total (000s)
Spleen size (cm) below the costal margin in PMF patients, total (000s)
Incidence of thrombosis, total (000s)
Thrombosis outcome in patients, total (000s)
Prevalence of JAK2-VG17F mutation, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of PMF by 5-yr age cohort, males (000s)
USA Prevalence of PMF by 5-yr age cohort, females (000s)
France Prevalence of PMF by 5-yr age cohort, males (000s)
France Prevalence of PMF by 5-yr age cohort, females (000s)
Germany Prevalence of PMF by 5-yr age cohort, males (000s)
Germany Prevalence of PMF by 5-yr age cohort, females (000s)
Italy Prevalence of PMF by 5-yr age cohort, males (000s)
Italy Prevalence of PMF by 5-yr age cohort, females (000s)
Spain Prevalence of PMF by 5-yr age cohort, males (000s)
Spain Prevalence of PMF by 5-yr age cohort, females (000s)
United Kingdom Prevalence of PMF by 5-yr age cohort, males (000s)
United Kingdom Prevalence of PMF by 5-yr age cohort, females (000s)
Brazil Prevalence of PMF by 5-yr age cohort, males (000s)
Brazil Prevalence of PMF by 5-yr age cohort, females (000s)
Japan Prevalence of PMF by 5-yr age cohort, males (000s)
Japan Prevalence of PMF by 5-yr age cohort, females (000s)


More Publications